Prediction of Disease Free Survival in Laryngeal and Hypopharyngeal Cancers Using CT Perfusion and Radiomic Features: A Pilot Study

Abstract

(1) Purpose: The objective was to evaluate CT perfusion and radiomic features for prediction of one year disease free survival in laryngeal and hypopharyngeal cancer. (2) Method and Materials: This retrospective study included pre and post therapy CT neck studies in 36 patients with laryngeal/hypopharyngeal cancer. Tumor contouring was performed semi-autonomously by the computer and manually by two radiologists. Twenty-six radiomic features including morphological and gray-level features were extracted by an internally developed and validated computer-aided image analysis system. The five perfusion features analyzed included permeability surface area product (PS), blood flow (flow), blood volume (BV), mean transit time (MTT), and time-to-maximum (Tmax). One year persistent/recurrent disease data were obtained following the final treatment of definitive chemoradiation or after total laryngectomy. We performed a two-loop leave-one-out feature selection and linear discriminant analysis classifier with generation of receiver operating characteristic (ROC) curves and confidence intervals (CI). (3) Results: 10 patients (28%) had recurrence/persistent disease at 1 year. For prediction, the change in blood flow demonstrated a training AUC of 0.68 (CI 0.47–0.85) and testing AUC of 0.66 (CI 0.47–0.85). The best features selected were a combination of perfusion and radiomic features including blood flow and computer-estimated percent volume changes-training AUC of 0.68 (CI 0.5–0.85) and testing AUC of 0.69 (CI 0.5–0.85). The laryngoscopic percent change in volume was a poor predictor with a testing AUC of 0.4 (CI 0.16–0.57). (4) Conclusions: A combination of CT perfusion and radiomic features are potential predictors of one-year disease free survival in laryngeal and hypopharyngeal cancer patients.

Nursing Observation on the Clinical Efficacy and Toxicity of Lobaplatin Compared with Cisplatin in the Treatment of Locally Advanced Hypopharyngeal Carcinoma Based on Intelligent CT Imaging

“…Therefore, in addition to the current conventional treatments, a better understanding of the process of tumor occurrence and development can increase the possibility that gene therapy will become another new treatment method for hypopharyngeal cancer. Moreover, hypopharyngeal cancer shows low sensitivity to anticancer drugs, and its underlying mechanism is still unknown, which also leads to a poor prognosis and a low five-year survival rate for patients with hypopharyngeal cancer [ 27 , 28 ]. Therefore, research and development of new treatment methods to reduce the antichemotherapy effect of hypopharyngeal cancer and improve its five-year survival rate are considered to be a new challenge [ 29 ].…”

Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl‐xL inhibitor

“…Additionally, traditional radiographic response criteria, as used in this study, failed to capture treatment efficacy in its entirety. 18 Thus, improved noninvasive biomarkers are needed to help predict responses to induction therapy, ultimately leading to improvements in rates of organ preservation and overall survival.…”

Multimodality CT imaging contributes to improving the diagnostic accuracy of solitary pulmonary nodules: a multi-institutional and prospective study

“…CTPI can be used to evaluate the perfusion and vascularity of lesions in the lung and many other organs. [21][22][23][24][25][26][27][28] Wang et al 21 reported that parameters of CTPI (including BF, BV and PS but not MTT) of SPNs were significantly correlated with SPNs' microvessel density (MVD) and luminal vascular parameters such as luminal vascular number (LVN), luminal vascular area (LVA), and luminal vascular perimeter (LVP). Huang et al 22 analyzed the CT perfusion parameters (BF, BV, MTT, and PS) and the microvessel parameters (MVD, LVN, LVA, and LVP) in the non-small cell lung cancer (NSCLC) patients with and without lymph node metastasis.…”